GLP-3

GLP-3

Price range: $100.00 through $225.00

Research Use Only | Not for Human Consumption

A synthetic peptide agonist of the GLP-1, GIP, and glucagon receptors, supplied in lyophilized form.

Published February 4, 2026 · Reviewed by the Peptide Foundry Research Team

GLP-3 is a synthetic peptide characterized in published research as a triple agonist at the GLP-1, GIP, and glucagon receptors. It has been examined in preclinical models of incretin and glucagon receptor signaling.

CAS#FormulaMolar Mass
2381089-83-2C₂₂₁H₃₄₂N₄₆O₆₈4731.3 g/mol

All products are shipped in lyophilized form and must be reconstituted for in-vitro research applications. Refer to the Certificate of Analysis for purity and identity specifications.

Join Foundry Club$50/monthGet this for $75 — Save $25

A synthetic triple-agonist peptide developed as a GLP-1/GIP/glucagon receptor research compound

Category: ,

What is GLP-3?

GLP-3 is a synthetic peptide characterized in published research as an agonist at the GLP-1, GIP, and glucagon (GCGR) receptors, with engineered potency ratios across the three targets. It is used as a laboratory tool for investigating incretin and glucagon receptor signaling in cellular and in vitro model systems.

Its triple-receptor profile has been examined in preclinical research as a reference compound for probing receptor crosstalk and downstream signaling cascades that are not accessible with single- or dual-receptor ligands.

GLP-3 has been referenced in peer-reviewed publications examining incretin receptor pharmacology. This product is intended for research use only.

What is GLP-3 studied for?

The following research areas represent documented studies available in the scientific literature. We make no claims regarding the benefits, efficacy, or therapeutic applications of this product.

Triple Receptor Agonism Research

In preclinical models, GLP-3 has been investigated for concurrent binding at GLP-1, GIP, and glucagon receptors.

View Studies (1)

GLP-1 Receptor Signaling Research

Published investigations have examined GLP-3's interactions with the GLP-1 receptor in cellular assays.

View Studies (1)

GIP Receptor Research

Laboratory studies have examined GLP-3's binding characteristics at the glucose-dependent insulinotropic polypeptide (GIP) receptor.

View Studies (1)

Glucagon Receptor Research

In vitro investigations have examined GLP-3's engagement with the glucagon receptor (GCGR) and downstream cAMP signaling.

View Studies (1)

Hepatic Signaling Research

Preclinical investigations have examined GLP-3's interactions with hepatic glucagon receptor pathways in metabolic model systems.

View Studies (1)

Pharmacokinetic Research

Published studies have characterized GLP-3's pharmacokinetic and pharmacodynamic profiles across research cohorts.

View Studies (1)

How should GLP-3 be stored?

All of our products are manufactured using the Lyophilization (Freeze Drying) process, which ensures that our products remain 100% stable for shipping for up to 3-4 months.

Once the peptides are reconstituted (mixed with bacteriostatic water), they must be stored in the fridge to maintain stability.

After reconstitution, the peptides will remain stable for up to 30 days.

Certificate of Analysis

All GLP-3 batches are independently tested by a third-party laboratory for purity and identity verification via HPLC with UV detection coupled with Mass Spectrometry.

HPLC Purity

—

COA documents are updated with each new batch. Contact support for batch-specific documentation.

Related Research Compounds

Frequently purchased with GLP-3

AOD-9604

AOD-9604

5mg

$75

MOTS-C

MOTS-C

10mg

$60

CJC-1295 + Ipamorelin

CJC-1295 + Ipamorelin

5mg/5mg

$85

Add all 3 items to your cart

$220

Clinical References

  1. Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism. 2022;34(9):1234-1247. PubMed: 35985340
  2. Jastreboff AM, et al. Triple-hormone-receptor agonist glp-3 for obesity u2014 a phase 2 trial. New England Journal of Medicine. 2023;389(6):514-526. PubMed: 37366315
  3. Rosenstock J, et al. GLP-3, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. The Lancet. 2023;402(10401):529-544. PubMed: 37385280
  4. Loomba R, et al. Triple hormone receptor agonist glp-3 for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024;30(7):2024-2033. PubMed: 38858523

GLP-3 is available for laboratory research purposes only.

© 2026 Peptide Foundry LLC | Product Catalog | Research Use Only

Related products

Welcome!

I understand these products are for research use only and not for use in people or pets. I am purchasing these items for laboratory or research purposes only. They are not for human or animal use, not medicine, and not for diagnosing, treating, or curing any condition. I will follow all applicable laws and safe handling rules. I accept that this website, and our affiliates, are not responsible for how I use or store these items once delivered, to the fullest extent allowed by law. In accordance with industry guidelines, access to this website is restricted to individuals 21 years of age or older. This site provides information and products strictly for laboratory and research use. Are you over 21 years of age?

I am I am not

Remember Me
Disclaimer: -Peptides: This product is intended for laboratory research use only and is not approved for human consumption, medical, or veterinary use. Peptides are sold solely for research and development purposes by qualified professionals. Buyers are responsible for handling all materials in accordance with local regulations and safety guidelines. Waave Compliance blocks all international shipping. FDA disclaimer: The statements made regarding these products have not been evaluated by the Food and Drug Administration. The efficacy of these products has not been confirmed by FDA-approved research. These products are not intended to diagnose, treat, cure, or prevent any disease.